Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Ani Pharmaceuticals (ANIP) over the last 17 years, with Sep 2025 value amounting to $262.6 million.

  • Ani Pharmaceuticals' Cash & Equivalents rose 81.13% to $262.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.6 million, marking a year-over-year increase of 81.13%. This contributed to the annual value of $144.9 million for FY2024, which is 34.49% down from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Cash & Equivalents stood at $262.6 million, which was up 20.58% from $217.8 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Cash & Equivalents peaked at $262.6 million during Q3 2025, and registered a low of $15.3 million during Q3 2021.
  • Over the past 3 years, Ani Pharmaceuticals' median Cash & Equivalents value was $193.1 million (recorded in 2023), while the average stood at $184.8 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Cash & Equivalents skyrocketed by 1,175.43% in 2021 and then plummeted by 51.92% in 2022.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Cash & Equivalents stood at $100.3 million in 2021, then plummeted by 51.92% to $48.2 million in 2022, then soared by 358.49% to $221.1 million in 2023, then plummeted by 34.49% to $144.9 million in 2024, then surged by 81.13% to $262.6 million in 2025.
  • Its Cash & Equivalents stands at $262.6 million for Q3 2025, versus $217.8 million for Q2 2025 and $149.8 million for Q1 2025.